[ad_1]
© Reuters. FILE PHOTO: The Regeneron Prescription drugs firm brand is seen on a constructing on the firm’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photograph(Reuters) – Regeneron Prescription drugs Inc (NASDAQ:) reported an about 46% plunge in its fourth-quarter revenue on Friday, harm by a drop in U.S. gross sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail gross sales.
The corporate recorded no gross sales within the quarter for its COVID-19 antibody drug as a result of U.S. regulator’s choice to restrict its use in January final yr in all states due to an absence of effectiveness towards the Omicron variant.
Gross sales of Eylea, used to deal with imaginative and prescient loss inflicting age-related macular degeneration, have been impacted by momentary closing of a fund throughout the quarter that gives co-pay help to sufferers.
The corporate’s web revenue fell to $1.20 billion, or $10.50 per share, within the quarter ended Dec. 31, from $2.23 billion, or $19.69 per share, a yr earlier.
[ad_2]